LIVIVO - Search results -

Search results

Result 1 - 10 of total 199

Search options

Book: The role of surrogate markers in the management of men with metastatic castration resistant prostate cancer

Armstrong, Andrew J. / Ferrari, Anna C. / Quinn, David I.

(Clinical advances in hematology & oncology ; 9,12, Suppl. 28 : Clinical roundtable monograph)

2011

Title variant	The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer
Author's details	moderator Andrew J. Armstrong. Discussants Anna C. Ferrari ; Daivd I. Quinn
Series title	Clinical advances in hematology & oncology ; 9,12, Suppl. 28 : Clinical roundtable monograph
Collection
Language	English
Size	15 S. : Ill.
Publisher	Millennium Med. Publ
Publishing place	New York, NY
Publishing country	United States
Document type	Book
HBZ-ID	HT017150400
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 6505 -9,Suppl.28-	verfügbar in Königswinter	Königswinter

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Oligometastatic Prostate Cancer: Current Status and Future Challenges.

Jadvar, Hossein / Abreu, Andre Luis / Ballas, Leslie K / Quinn, David I

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

2022 Volume 63, Issue 11, Page(s) 1628–1635

Abstract: In accordance with the spectrum theory of metastatic disease, an oligometastatic clinical state has been proposed as an intermediary step along the natural history of cancer with few (typically 1-3) metastatic lesions identifiable on imaging that may be ... ...

Abstract	In accordance with the spectrum theory of metastatic disease, an oligometastatic clinical state has been proposed as an intermediary step along the natural history of cancer with few (typically 1-3) metastatic lesions identifiable on imaging that may be amenable to metastasis-directed therapy. Effective therapy of oligometastatic disease is anticipated to impact cancer evolution by delaying progression and improving patient outcome at a minimal or acceptable cost of toxicity. There has been increasing recognition of oligometastatic disease in prostate cancer with the advent of new-generation imaging agents, most notably the recently approved PET radiotracers based on targeting prostate-specific membrane antigen. Early clinical trials with metastasis-directed therapy of oligometastases have provided evidence for delaying the employment of systematic therapy and improving outcome in selected patients. Despite these encouraging results, much needs to be investigated and learned about the underlying biology of the oligometastatic state along the evolutionary clinical course of prostate cancer, the identification of relevant imaging and nonimaging predictive and prognostic biomarkers, and the development of treatment strategies to optimize short-term and long-term patient outcome. We provide a review of the current status and the lingering challenges of this rapidly evolving clinical space in prostate cancer.
MeSH term(s)	Male ; Humans ; Prostatic Neoplasms/pathology
Language	English
Publishing date	2022-10-29
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	80272-4
ISSN	1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
ISSN (online)	1535-5667
ISSN	0097-9058 ; 0161-5505 ; 0022-3123
DOI	10.2967/jnumed.121.263124
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 328: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape.

D'souza, Anishka A / Tulpule, Varsha / Zang, Peter D / Quinn, David I

Annals of oncology : official journal of the European Society for Medical Oncology

2022 Volume 33, Issue 3, Page(s) 242–243

MeSH term(s)	Humans ; Urinary Bladder Neoplasms/therapy ; Wilderness
Language	English
Publishing date	2022-02-10
Publishing country	England
Document type	Editorial ; Comment
ZDB-ID	1025984-3
ISSN	1569-8041 ; 0923-7534
ISSN (online)	1569-8041
ISSN	0923-7534
DOI	10.1016/j.annonc.2022.01.073
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2862: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.

Tulpule, Varsha / Morrison, Gareth J / Falcone, Mary / Quinn, David I / Goldkorn, Amir

Current oncology reports

2022 Volume 24, Issue 10, Page(s) 1287–1298

Abstract: Purpose of review: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer.: Recent findings: To date, ... ...

Abstract	Purpose of review: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer. Recent findings: To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.
MeSH term(s)	Biomarkers, Tumor/genetics ; Humans ; Liquid Biopsy ; Male ; Neoplastic Cells, Circulating/pathology ; Prognosis ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2022-05-16
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, N.I.H., Extramural
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-022-01278-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Editorial Comment.

D'Souza, Anishka A / Quinn, David I

The Journal of urology

2019 Volume 203, Issue 2, Page(s) 336–337

Language	English
Publishing date	2019-10-29
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	3176-8
ISSN	1527-3792 ; 0022-5347
ISSN (online)	1527-3792
ISSN	0022-5347
DOI	10.1097/01.JU.0000612372.02047.48
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.91: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 331: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.

Quinn, David I / Lara, Primo N

The New England journal of medicine

2015 Volume 373, Issue 19, Page(s) 1872–1874

MeSH term(s)	Anilides/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Carcinoma, Renal Cell/drug therapy ; Female ; Humans ; Kidney Neoplasms/drug therapy ; Male ; Pyridines/therapeutic use ; Sirolimus/analogs & derivatives
Chemical Substances	Anilides ; Antibodies, Monoclonal ; Antineoplastic Agents ; Pyridines ; Sirolimus (W36ZG6FT64)
Language	English
Publishing date	2015-09-25
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMe1511252
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.

Feng, Zizhen / Curti, Brendan D / Quinn, David I / Strother, John M / Chen, Zunqiu / Agnor, Rebecca / Beer, Tomasz M / Ryan, Christopher W

Clinical genitourinary cancer

2022 Volume 20, Issue 5, Page(s) 415–422

Abstract: Background: Overexpression of the epidermal growth factor receptor (EGFR) and its ligands occur frequently in renal cell carcinoma (RCC). Combined vascular endothelial growth factor receptor (VEGF-R) and EGFR inhibition may overcome resistance to VEGF-R ...

Abstract	Background: Overexpression of the epidermal growth factor receptor (EGFR) and its ligands occur frequently in renal cell carcinoma (RCC). Combined vascular endothelial growth factor receptor (VEGF-R) and EGFR inhibition may overcome resistance to VEGF-R inhibitor monotherapy. We performed a dose-escalation phase II study of sunitinib plus erlotinib in advanced renal cell carcinoma. Patients and methods: Patients with metastatic clear cell or papillary RCC were eligible. Prior therapy was allowed except sunitinib or erlotinib. Three dose levels of erlotinib (50, 100, 150 mg daily) were evaluated in combination with sunitinib 50 mg. Thirty-seven patients were treated at maximum tolerated dose to determine efficacy. The primary endpoint was 8-month progression-free survival (PFS) rate. The trial was powered to assess for a difference between a median PFS of less than 50% with a targeted 70% PFS for the combination. Results: The 8-month PFS rate was 40% (95% CI: 23-56). Median PFS was 5.8 months (95% CI: 4.1-9.7) and median overall survival (OS) was 26.3 months (95% CI: 16.1-34.0). The objective response rate was 22% and an additional 59% of patients had stable disease for at least 6 weeks. The most common adverse events for all grades were diarrhea, rash, fatigue, and dysgeusia. Dose reduction in 1 or both of the drugs was undertaken in 17 (46%) patients, while 5 (14%) discontinued study therapy due to toxicity. Conclusion: While sunitinib and erlotinib are combinable,the 8-month PFS rate did not suggest efficacy improvement over sunitinib monotherapy (NCT00425386).
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Renal Cell/pathology ; Disease-Free Survival ; ErbB Receptors ; Erlotinib Hydrochloride/adverse effects ; Humans ; Kidney Neoplasms/pathology ; Receptors, Vascular Endothelial Growth Factor ; Sunitinib/therapeutic use ; Vascular Endothelial Growth Factor A
Chemical Substances	Vascular Endothelial Growth Factor A ; Erlotinib Hydrochloride (DA87705X9K) ; ErbB Receptors (EC 2.7.10.1) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Sunitinib (V99T50803M)
Language	English
Publishing date	2022-05-05
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2225121-2
ISSN	1938-0682 ; 1558-7673
ISSN (online)	1938-0682
ISSN	1558-7673
DOI	10.1016/j.clgc.2022.04.018
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.

Lara, Primo N / Mayerson, Edward / Gertz, Erik / Tangen, Catherine / Goldkorn, Amir / van Loan, Marta / Hussain, Maha / Gupta, Shilpa / Zhang, Jingsong / Parikh, Mamta / Twardowski, Przemyslaw / Quinn, David I / LeBlanc, Michael / Thompson, Ian / Agarwal, Neeraj

Prostate cancer and prostatic diseases

2024

Language	English
Publishing date	2024-02-29
Publishing country	England
Document type	Journal Article
ZDB-ID	1419277-9
ISSN	1476-5608 ; 1365-7852
ISSN (online)	1476-5608
ISSN	1365-7852
DOI	10.1038/s41391-024-00813-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5277: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.

Velez, Erik M / Desai, Bhushan / Ji, Lingyun / Quinn, David I / Colletti, Patrick M / Jadvar, Hossein

Theranostics

2020 Volume 10, Issue 7, Page(s) 3254–3262

Abstract: Accurate appraisal of treatment response in metastatic castrate-resistant prostate cancer (mCRPC) is challenging in view of remarkable tumor heterogeneity and the available choices among many established and novel therapeutic approaches. The purpose of ... ...

Abstract	Accurate appraisal of treatment response in metastatic castrate-resistant prostate cancer (mCRPC) is challenging in view of remarkable tumor heterogeneity and the available choices among many established and novel therapeutic approaches. The purpose of this single-center prospective study was to evaluate the comparative prognostic utility of PERCIST 1.0 in predicting overall survival (OS) in patients with mCRPC compared to RECIST 1.1 and prostate-specific antigen (PSA)-based treatment response assessments.
MeSH term(s)	Adenocarcinoma/blood ; Adenocarcinoma/diagnostic imaging ; Adenocarcinoma/drug therapy ; Adenocarcinoma/mortality ; Disease Progression ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 ; Humans ; Kallikreins/blood ; Kaplan-Meier Estimate ; Male ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/mortality ; Radiopharmaceuticals ; Tomography, Spiral Computed ; Treatment Outcome
Chemical Substances	Fluorine Radioisotopes ; Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; KLK3 protein, human (EC 3.4.21.-) ; Kallikreins (EC 3.4.21.-) ; Prostate-Specific Antigen (EC 3.4.21.77) ; Fluorine-18 (GZ5I74KB8G)
Language	English
Publishing date	2020-02-10
Publishing country	Australia
Document type	Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2592097-2
ISSN	1838-7640 ; 1838-7640
ISSN (online)	1838-7640
ISSN	1838-7640
DOI	10.7150/thno.39838
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials.

Wong, Sarah E / Quinn, David I / Bjarnason, Georg A / North, Scott A / Sridhar, Srikala S

American journal of clinical oncology

2020 Volume 43, Issue 8, Page(s) 559–566

Abstract: Objectives: Treatments for metastatic renal cell carcinoma (mRCC) are often compared across trials, but trial eligibility criteria and endpoints differ. In an effort to better align trials, the Definition for the Assessment of Time to event Endpoints in ...

Abstract	Objectives: Treatments for metastatic renal cell carcinoma (mRCC) are often compared across trials, but trial eligibility criteria and endpoints differ. In an effort to better align trials, the Definition for the Assessment of Time to event Endpoints in CANcer trials (DATECAN) project published recommendations in 2015 to be used in mRCC clinical trial design. We analyzed mRCC trial criteria to determine if DATECAN's recommendations were followed. Materials and methods: We compared eligibility criteria across 29 phase 3 mRCC trials conducted between 2003 and 2019. We then evaluated endpoints used in 10 phase 3 trials activated between 2015 and 2019 to determine their compliance with DATECAN's recommendations. Results: Among the 29 trials, performance status, renal function, and disease characteristics differed in terms of requirements and measures used. In terms of endpoints, the 10 trials did not entirely follow DATECAN's recommendations. In total, 7/10 trials' primary endpoint was progression-free survival (PFS) as recommended; 4/9 trials used PFS as an endpoint but did not publish their definition of PFS, and the 5 that did, included "death from any cause" instead of DATECAN's recommendation of "death from kidney cancer." Conclusions: Key eligibility criteria were somewhat inconsistent across the phase 3 mRCC trials studied. Endpoints in the newer trials did not align with DATECAN's recommendations. Not only is greater standardization needed to facilitate meta-analyses and cross-trial comparisons, but as evident from lack of adherence to DATECAN's recommendations, greater promotion and adoption of recommendations are needed to better harmonize trial design.
MeSH term(s)	Carcinoma, Renal Cell/secondary ; Carcinoma, Renal Cell/therapy ; Eligibility Determination/standards ; Humans ; Kidney Neoplasms/pathology ; Kidney Neoplasms/therapy ; Randomized Controlled Trials as Topic/standards
Language	English
Publishing date	2020-05-12
Publishing country	United States
Document type	Comparative Study ; Journal Article
ZDB-ID	604536-4
ISSN	1537-453X ; 0277-3732
ISSN (online)	1537-453X
ISSN	0277-3732
DOI	10.1097/COC.0000000000000705
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1557: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito